(Q38714374)

5 September 2017

Patient-derived xenografts as in vivo models for research in urological malignancies (English)

1 reference

5 September 2017

1 reference

Takahiro Inoue

1

1 reference

5 September 2017

Naoki Terada

series ordinal

2

1 reference

5 September 2017

Takashi Kobayashi

series ordinal

3

1 reference

5 September 2017

Osamu Ogawa

series ordinal

4

1 reference

5 September 2017

language of work or name

English

0 references

publication date

21 February 2017

1 reference

5 September 2017

Nature Reviews Urology

1 reference

5 September 2017

14

1 reference

5 September 2017

267-283

1 reference

5 September 2017

5

1 reference

https://scigraph.springernature.com/pub.10.1038/nrurol.2017.19

5 September 2017

0 references

cites work

Can the pharmaceutical industry reduce attrition rates?

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Trial watch: phase II and phase III attrition rates 2011-2012.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Clinical Approval Success Rates for Investigational Cancer Drugs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Patient-derived xenograft models: an emerging platform for translational cancer research

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Patient-derived tumour xenografts as models for oncology drug development

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

One mouse, one patient paradigm: New avatars of personalized cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Establishment of human tumor xenografts in immunodeficient mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Of mice and men--warning: intact versus castrated adult male mice as xenograft hosts are equivalent to hypogonadal versus abiraterone treated aging human males, respectively

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

An Integrative Approach to Precision Cancer Medicine Using Patient-Derived Xenografts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

The development of androgen-independent prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Experimental evidence of persistent androgen-receptor-dependency in castration-resistant prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

A preclinical xenograft model identifies castration-tolerant cancer-repopulating cells in localized prostate tumors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Prostatic adenocarcinoma PC EW, a new human tumor line transplantable in nude mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Use of nude mouse xenograft models in prostate cancer research

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Xenografts of primary human prostatic carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Chromosomal aberrations in prostate cancer xenografts detected by comparative genomic hybridization

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

A neuroendocrine/small cell prostate carcinoma xenograft-LuCaP 49

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Characterization of a transplantable hormone-responsive human prostatic cancer xenograft TEN12 and its androgen-resistant sublines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

BM18: A novel androgen-dependent human prostate cancer xenograft model derived from a bone metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

A novel androgen-dependent prostate cancer xenograft model derived from skin metastasis of a Japanese patient.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Human prostatic adenocarcinoma: Some characteristics of a serially transplantable line in nude mice (PC 82)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

The human PC346 xenograft and cell line panel: a model system for prostate cancer progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Androgen receptor splice variants determine taxane sensitivity in prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Metastatic phenotype in CWR22 prostate cancer xenograft following castration

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

LuCaP 35: A new model of prostate cancer progression to androgen independence

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Molecular determinants of resistance to antiandrogen therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Identification of EP4 as a potential target for the treatment of castration-resistant prostate cancer using a novel xenograft model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

An original patient-derived xenograft of prostate cancer with cyst formation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Dopamine 5 receptor mediates Ang II type 1 receptor degradation via a ubiquitin-proteasome pathway in mice and human cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Identification of Bone-Derived Factors Conferring De Novo Therapeutic Resistance in Metastatic Prostate Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Small cell carcinoma of the prostate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Modeling a lethal prostate cancer variant with small-cell carcinoma features

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Neuroendocrine prostate cancer xenografts with large-cell and small-cell features derived from a single patient's tumor: morphological, immunohistochemical, and gene expression profiles

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Establishing a human renal cell carcinoma tumorgraft platform for preclinical drug testing

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Development and characterization of clinically relevant tumor models from patients with renal cell carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Overrepresentation of 7q31 and 17q in renal cell carcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient-Derived Xenograft Models.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Dll4 blockade potentiates the anti-tumor effects of VEGF inhibition in renal cell carcinoma patient-derived xenografts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Tissue slice grafts of human renal cell carcinoma: an authentic preclinical model with high engraftment rate and metastatic potential.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Development of a realistic in vivo bone metastasis model of human renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Inhibition of angiogenic and non-angiogenic targets by sorafenib in renal cell carcinoma (RCC) in a RCC xenograft model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Orthotopic xenografts of RCC retain histological, immunophenotypic and genetic features of tumours in patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Sorafenib in advanced clear-cell renal-cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Targeting renal cell carcinoma with a HIF-2 antagonist.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

CCL2 as a potential therapeutic target for clear cell renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

MEK inhibition abrogates sunitinib resistance in a renal cell carcinoma patient-derived xenograft model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Establishment of a large panel of patient-derived preclinical models of human renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Urothelial carcinoma of the bladder: definition, treatment and future efforts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

The growth of human bladder and kidney cancers as xenografts in nude mice and rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Patient-derived bladder cancer xenografts: a systematic review.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Basal Tumor Cell Isolation and Patient-Derived Xenograft Engraftment Identify High-Risk Clinical Bladder Cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Modelling bladder cancer in mice: opportunities and challenges

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Molecular characterization of upper urinary tract tumours.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Genomic Characterization of Upper Tract Urothelial Carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Establishment and characterization of human urothelial cancer xenografts in severe combined immunodeficient mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Development and characterization of a bladder cancer xenograft model using patient-derived tumor tissue.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Development and characteristics of preclinical experimental models for the research of rare neuroendocrine bladder cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

YAP activation protects urothelial cell carcinoma from treatment-induced DNA damage

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Patient-derived bladder cancer xenografts in the preclinical development of novel targeted therapies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Features of squamous and adenocarcinoma in the same cell in a xenografted human transitional cell carcinoma: evidence of a common histogenesis?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

The growth and histological characteristics of a series of human bladder cancer xenografts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Patient-derived xenografts reveal limits to PI3K/mTOR- and MEK-mediated inhibition of bladder cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

A preclinical xenograft model of prostate cancer using human tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Human xenograft models as useful tools to assess the potential of novel therapeutics in prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Determination of subcutaneous tumor size in athymic (nude) mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

The SCID mouse mutant: definition, characterization, and potential uses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Humanized mice for immune system investigation: progress, promise and challenges

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Defective lymphoid development in mice lacking expression of the common cytokine receptor gamma chain.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Non-obese diabetic-recombination activating gene-1 (NOD-Rag1 null) interleukin (IL)-2 receptor common gamma chain (IL2r gamma null) null mice: a radioresistant model for human lymphohaematopoietic engraftment.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Current advances in humanized mouse models

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Patient-derived breast tumor xenografts facilitating personalized cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Development and characterization of efficient xenograft models for benign and malignant human prostate tissue

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Orthotopic tumorgrafts in nude mice: A new method to study human prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Ultrasound-guided intramural inoculation of orthotopic bladder cancer xenografts: a novel high-precision approach

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Spatial genomic heterogeneity within localized, multifocal prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Whole-genome sequencing identifies genomic heterogeneity at a nucleotide and chromosomal level in bladder cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Biobanking of patient and patient-derived xenograft ovarian tumour tissue: efficient preservation with low and high fetal calf serum based methods

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Cryopreservation of human colorectal carcinomas prior to xenografting

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Successful xenografting of cryopreserved primary pancreatic cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Next generation patient-derived prostate cancer xenograft models

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

In vivo horizontal oncogenesis by a human tumor in nude mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Tumour-induced host stromal-cell transformation: induction of mouse spindle-cell fibrosarcoma not mediated by gene transfer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Patient-Derived Tumor Xenografts Are Susceptible to Formation of Human Lymphocytic Tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Early development of human lymphomas in a prostate cancer xenograft program using triple knock-out immunocompromised mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Spontaneous Post-Transplant Disorders in NOD.Cg- Prkdcscid Il2rgtm1Sug/JicTac (NOG) Mice Engrafted with Patient-Derived Metastatic Melanomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Normal, bound and nonbound testosterone levels in normally ageing men: results from the Massachusetts Male Ageing Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Adrenal glands of mouse and rat do not synthesize androgens

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

XMRV accelerates cellular proliferation, transformational activity, and invasiveness of prostate cancer cells by downregulating p27(Kip1).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Infection of Xenotransplanted Human Cell Lines by Murine Retroviruses: A Lesson Brought Back to Light by XMRV.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Patient-derived xenografts, the cancer stem cell paradigm, and cancer pathobiology in the 21st century

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Hallmarks of Cancer: The Next Generation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Differentially methylated genes and androgen receptor re-expression in small cell prostate carcinomas.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

BMP4 promotes prostate tumor growth in bone through osteogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Secretome analysis of an osteogenic prostate tumor identifies complex signaling networks mediating cross-talk of cancer and stromal cells within the tumor microenvironment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Acquired resistance to endocrine treatments is associated with tumor-specific molecular changes in patient-derived luminal breast cancer xenografts.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Microenvironment-Modulated Metastatic CD133+/CXCR4+/EpCAM- Lung Cancer-Initiating Cells Sustain Tumor Dissemination and Correlate with Poor Prognosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Anti-estrogen Resistance in Human Breast Tumors Is Driven by JAG1-NOTCH4-Dependent Cancer Stem Cell Activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Integrated next-generation sequencing and avatar mouse models for personalized cancer treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

High-throughput simultaneous screen and counterscreen identifies homoharringtonine as synthetic lethal with von Hippel-Lindau loss in renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Development and function of human innate immune cells in a humanized mouse model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Stromal gene expression defines poor-prognosis subtypes in colorectal cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Stromal contribution to the colorectal cancer transcriptome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

A 3D in vitro model of patient-derived prostate cancer xenograft for controlled interrogation of in vivo tumor-stromal interactions.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Establishment and characterization of a cell line from human circulating colon cancer cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2017.19

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.

31 March 2020

1 reference

12 December 2020

Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms

1 reference

12 December 2020

A human prostatic epithelial model of hormonal carcinogenesis

1 reference

12 December 2020

Bladder cancer xenografts: a model of tumor cell heterogeneity

1 reference

12 December 2020

Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process

1 reference

12 December 2020

Minimally invasive establishment of murine orthotopic bladder xenografts

1 reference

12 December 2020

Human cancer growth and therapy in immunodeficient mouse models

1 reference

12 December 2020

CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar.

1 reference

12 December 2020

Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice

1 reference

12 December 2020

Heterotransplantation of human urinary bladder cancers in nude mice

1 reference

12 December 2020

Genomic profiling is predictive of response to cisplatin treatment but not to PI3K inhibition in bladder cancer patient-derived xenografts

1 reference

12 December 2020

Xenografts of human bladder cancer in immune-deprived mice

1 reference

12 December 2020

Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe-combined-immunodeficient mouse model

1 reference

12 December 2020

Patient-derived sialyl-Tn-positive invasive bladder cancer xenografts in nude mice: an exploratory model study

1 reference

12 December 2020

Stability of preclinical models of aggressive renal cell carcinomas

1 reference

12 December 2020

In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR).

1 reference

12 December 2020

Generation of Prostate Cancer Patient Derived Xenograft Models from Circulating Tumor Cells

1 reference

12 December 2020

Orthotopic transplantation model of human gastrointestinal cancer and detection of micrometastases

1 reference

12 December 2020

Antiandrogen withdrawal syndrome and alternative antiandrogen therapy associated with the W741C mutant androgen receptor in a novel prostate cancer xenograft

1 reference

12 December 2020

Characterization of a novel androgen-sensitive, prostate-specific antigen-producing prostatic carcinoma xenograft: LuCaP 23.

1 reference

12 December 2020

Heterotransplantation of Human Transitional Cell Carcinoma in Athymic Mice

1 reference

12 December 2020

Humanized SCID mouse models for biomedical research

1 reference

12 December 2020

Patient-derived xenograft (PDX) tumors increase growth rate with time.

1 reference

12 December 2020

Development of seven new human prostate tumor xenograft models and their histopathological characterization.

1 reference

12 December 2020

Development of secondary structure, growth characteristics and cytogenetic analysis of human transitional cell carcinoma xenografts in scid/scid mice

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRUROL.2017.19

1 reference

Dimensions Publication ID

5 September 2017

0 references

1 reference